Prevents the establishment of the cellular antiviral state by inhibiting TRIM25-mediated DDX58 ubiquitination, which normally triggers the antiviral transduction signal that leads to the activation of type I IFN genes by transcription factors IRF3 and IRF7.
Prevents human EIF2AK2/PKR activation, either by binding double-strand RNA, or by interacting directly with EIF2AK2/PKR.
This function may be important at the very beginning of the infection, when NS1 is mainly present in the cytoplasm.
Also binds poly(A) and U6 snRNA.
Applications:Suitable for use in FLISA.
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:Store product at 4°C if to be used immediately within two weeks.
For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C.
Aliquots are stable at -20°C for 12 months after receipt.
Dilute required amount only prior to immediate use.
Further dilutions can be made in assay buffer.
Caution: FITC conjugates are sensitive to light.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ul
Host：rabbit
Source Antibody：Influenza A virus
Grade：Affinity Purified
Purity：Purified by Protein G affinity chromatography.
Form：Supplied as a liquid in 0.01M PBS, pH 7.4, 0.03% Proclin 300, 50% glycerol. Labeled with Fluorescein isothiocyanate (FITC).
Specificity：Recognizes influenza A virus NS.
Isotype：IgG
Calc Applications Abbrev：FLISA
Immunogen：Recombinant protein corresponding to aa1-237 from influenza A virus non-structural protein 1.
